These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9174332)

  • 1. Avoiding an impairment of factor VIII:C by using hydroxyethyl starch with a low in vivo molecular weight.
    Treib J; Haass A; Pindur G; Grauer MT; Wenzel E; Schimrigk K
    Anesth Analg; 1997 Jun; 84(6):1391. PubMed ID: 9174332
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of desmopressin and 6% hydroxyethyl starch on factor VIII:C.
    Conroy JM; Fishman RL; Reeves ST; Pinosky ML; Lazarchick J
    Anesth Analg; 1996 Oct; 83(4):804-7. PubMed ID: 8831325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihaemophilic effect of vasopressin, deamino-(D-arginine8)-vasopressin and adrenaline in sheep: proposal for an in vivo assay system.
    Heiniger J; Kissling-Albrecht L; Neuenschwander S; Rösli R; Pliska V
    Br J Pharmacol; 1988 Jun; 94(2):279-81. PubMed ID: 3134968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on bleeding time in uremic patients].
    Alarcón F; Mezzano D; Vial S; Pereira J
    Rev Med Chil; 1985 Aug; 113(8):763-8. PubMed ID: 3938558
    [No Abstract]   [Full Text] [Related]  

  • 5. Cryoprecipitate of intermediate purity produced in a closed thaw-siphon system from DDAVP stimulated blood donor plasma.
    Konecka G; Bykowska K; Ludwicka A; Letowska M; Wegrzynowicz Z; Sablinski J; Lopaciuk S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):565-70. PubMed ID: 1714861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus.
    Kobrinsky NL; Doyle JJ; Israels ED; Winter JS; Cheang MS; Walker RD; Bishop AJ
    Lancet; 1985 Jun; 1(8441):1293-4. PubMed ID: 2860491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of propranolol, barbiturate anesthesia and splenectomy on factor VIII:C and plasminogen activator release induced by DDAVP. An experimental study on the dog.
    Pina-Cabral JM; Cunha-Monteiro A; Sousa-Dias MC; Andrade JA
    Thromb Haemost; 1989 Sep; 62(2):784-7. PubMed ID: 2510352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced effect of exercise and DDAVP on factor VIII-von Willebrand Factor and plasminogen activator after sequential application of both the stimuli.
    Vicente V; Alberca I; Mannucci PM
    Thromb Haemost; 1984 Feb; 51(1):129-30. PubMed ID: 6426078
    [No Abstract]   [Full Text] [Related]  

  • 9. DDAVP, cryoprecipitate, and highly 'purified' factor VIII concentrate in uremia.
    Juhl A
    Nephron; 1986; 43(4):305-6. PubMed ID: 3090461
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of plasma expanders on coagulation and hemostasis: dextran hydroxyethyl starch, and other macromolecules revisited.
    Alexander B
    Prog Clin Biol Res; 1978; 19():293-330. PubMed ID: 78500
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effects of low molecular hydroxyethyl starch (HES) on the kidney -- a comparison with low molecular dextran].
    Yamasaki H
    Masui; 1975 Jun; 24(6):580-600. PubMed ID: 51106
    [No Abstract]   [Full Text] [Related]  

  • 12. Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.
    Ludlam CA; Peake IR; Allen N; Davies BL; Furlong RA; Bloom AL
    Br J Haematol; 1980 Jul; 45(3):499-511. PubMed ID: 6775673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on the properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) in normal individuals (author's transl)].
    Takahashi H; Itoh M; Kobayashi I; Hattori A; Takahashi K; Sakuragawa N; Shibata A; Tsukada T
    Nihon Ketsueki Gakkai Zasshi; 1980 Oct; 43(5):907-17. PubMed ID: 6785953
    [No Abstract]   [Full Text] [Related]  

  • 14. DDAVP-induced changes of factor VIII-related activities and bleeding time in patients with von Willebrand's syndrome.
    Schmitz-Huebner U; Balleisen L; Arends P; Pollmann H; Sutor AH
    Haemostasis; 1980; 9(4):204-13. PubMed ID: 6772527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desmopressin (DDAVP) and factor VIII.
    Ingram GI
    J Thromb Haemost; 2003 Sep; 1(9):2045-6; discussion 2046-7. PubMed ID: 12941049
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness, specificity and safety of intranasal 1-deamino-8-D-arginine vasopressin treatment of normal blood donors.
    Palmer DS; Harris AS; Tittley P; Rock G
    Haemostasis; 1988; 18(3):187-96. PubMed ID: 2972594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro.
    Ibbotson SH; Grant PJ; Kerry R; Findlay VS; Prentice CR
    Thromb Haemost; 1991 Jan; 65(1):64-6. PubMed ID: 1902596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery : a randomised, double-blind study.
    Jungheinrich C; Sauermann W; Bepperling F; Vogt NH
    Drugs R D; 2004; 5(1):1-9. PubMed ID: 14725484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of hydroxyethyl starches.
    Mishler JM
    Rev Fr Transfus Immunohematol; 1980; 23(3):283-98. PubMed ID: 6157397
    [No Abstract]   [Full Text] [Related]  

  • 20. Low- and medium-molecular-weight hydroxyethyl starches: comparison of their effect on blood coagulation.
    Jamnicki M; Bombeli T; Seifert B; Zollinger A; Camenzind V; Pasch T; Spahn DR
    Anesthesiology; 2000 Nov; 93(5):1231-7. PubMed ID: 11046211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.